These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22336962)

  • 1. Effects of alendronate and risedronate on bone material properties in actively forming trabecular bone surfaces.
    Hofstetter B; Gamsjaeger S; Phipps RJ; Recker RR; Ebetino FH; Klaushofer K; Paschalis EP
    J Bone Miner Res; 2012 May; 27(5):995-1003. PubMed ID: 22336962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Gamsjaeger S; Buchinger B; Zoehrer R; Phipps R; Klaushofer K; Paschalis EP
    Bone; 2011 Dec; 49(6):1160-5. PubMed ID: 21893225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.
    Allen MR; Iwata K; Phipps R; Burr DB
    Bone; 2006 Oct; 39(4):872-9. PubMed ID: 16765660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
    Durchschlag E; Paschalis EP; Zoehrer R; Roschger P; Fratzl P; Recker R; Phipps R; Klaushofer K
    J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate.
    Allen MR; Turek JJ; Phipps RJ; Burr DB
    Bone; 2011 Jul; 49(1):128-32. PubMed ID: 20637914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
    Hosking D; Adami S; Felsenberg D; Andia JC; Välimäki M; Benhamou L; Reginster JY; Yacik C; Rybak-Feglin A; Petruschke RA; Zaru L; Santora AC
    Curr Med Res Opin; 2003; 19(5):383-94. PubMed ID: 13678475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.
    Hofstetter B; Gamsjaeger S; Varga F; Dobnig H; Stepan JJ; Petto H; Pavo I; Klaushofer K; Paschalis EP
    Osteoporos Int; 2014 Dec; 25(12):2709-19. PubMed ID: 25037600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties.
    Hassler N; Gamsjaeger S; Hofstetter B; Brozek W; Klaushofer K; Paschalis EP
    Osteoporos Int; 2015 Jan; 26(1):339-52. PubMed ID: 25315260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.
    Borah B; Dufresne TE; Ritman EL; Jorgensen SM; Liu S; Chmielewski PA; Phipps RJ; Zhou X; Sibonga JD; Turner RT
    Bone; 2006 Aug; 39(2):345-52. PubMed ID: 16571382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid.
    Gamsjaeger S; Buchinger B; Zwettler E; Recker R; Black D; Gasser JA; Eriksen EF; Klaushofer K; Paschalis EP
    J Bone Miner Res; 2011 Jan; 26(1):12-8. PubMed ID: 20645415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization.
    Bala Y; Depalle B; Farlay D; Douillard T; Meille S; Follet H; Chapurlat R; Chevalier J; Boivin G
    J Bone Miner Res; 2012 Apr; 27(4):825-34. PubMed ID: 22189833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
    Zikan V; Stepan JJ
    Bone; 2009 Apr; 44(4):634-8. PubMed ID: 19150421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge.
    Spadaro JA; Damron TA; Horton JA; Margulies BS; Murray GM; Clemente DA; Strauss JA
    J Orthop Res; 2006 May; 24(5):936-44. PubMed ID: 16609966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).
    Roschger P; Lombardi A; Misof BM; Maier G; Fratzl-Zelman N; Fratzl P; Klaushofer K
    J Bone Miner Res; 2010 Jan; 25(1):48-55. PubMed ID: 19580465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.
    Gourion-Arsiquaud S; Allen MR; Burr DB; Vashishth D; Tang SY; Boskey AL
    Bone; 2010 Mar; 46(3):666-72. PubMed ID: 19925895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate.
    Bala Y; Farlay D; Chapurlat RD; Boivin G
    Eur J Endocrinol; 2011 Oct; 165(4):647-55. PubMed ID: 21821631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis.
    Stepan JJ; Burr DB; Pavo I; Sipos A; Michalska D; Li J; Fahrleitner-Pammer A; Petto H; Westmore M; Michalsky D; Sato M; Dobnig H
    Bone; 2007 Sep; 41(3):378-85. PubMed ID: 17597017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
    Adachi JD; Saag KG; Delmas PD; Liberman UA; Emkey RD; Seeman E; Lane NE; Kaufman JM; Poubelle PE; Hawkins F; Correa-Rotter R; Menkes CJ; Rodriguez-Portales JA; Schnitzer TJ; Block JA; Wing J; McIlwain HH; Westhovens R; Brown J; Melo-Gomes JA; Gruber BL; Yanover MJ; Leite MO; Siminoski KG; Nevitt MC; Sharp JT; Malice MP; Dumortier T; Czachur M; Carofano W; Daifotis A
    Arthritis Rheum; 2001 Jan; 44(1):202-11. PubMed ID: 11212161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.